Key Drivers
- Strong margins
- Heavy indebtedness
- Volatile net income
AIAI Summary
BHC's operations generate strong EBITDA and FCF, but equity upside now hinges on credible, sustained deleveraging (e.g., >$1B annual net debt reduction or one/two large asset sales) because very high absolute debt combined with IRA/Medicare pricing exposure for key brands and execution risk on refinancing/M&A are the dominant downside threats.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong margins
- •Heavy indebtedness
- •Volatile net income
BHC shows robust revenue, margins and free cash flow but is undermined by extreme leverage, negative equity and large intangibles that create material solvency risk and volatile net income.
Price Behavior
Key Price Behavior Insights:
- •Sharp decline
- •Below 21-day SMA
- •Defined support
BHC is in a clear short-term downtrend over the last month, falling ~18% from $6.13 to $5.01 and trading ~9% below its last-month 21-day SMA (~$5.52), holding near support at $4.96 with resistance at $6.10–$6.20.
~18% drop from $6.13 to $5.01 over the last month signaling accelerated selling pressure
Sentiment & News
Key News Insights:
- •Share-price decline
- •Securities probe
- •Canadian product launch
Bausch Health faces downward stock pressure and potential securities litigation even as its Solta aesthetics unit launches Clear + Brilliant Touch in Canada, signaling simultaneous legal/headwind risks and operational growth.
The legal investigation and recent selloff raise near-term downside risk, while the Solta launch offers modest revenue upside that likely won't offset short-term investor concerns
Similar Companies in Healthcare
Other companies in the same sector with AI ratings